Neurocrine To Refile Electronic NDA For Indiplon After Meeting With FDA

FDA refuses to file application for the immediate-release formulation of Pfizer/Neurocrine's insomnia agent "due to difficulties encountered in navigating the electronic NDA," Neurocrine says. An NDA for the modified-release formulation is under review and will require "modest" changes, company says.